Stryker (NYSE:SYK) Stock: Insider Ronda Stryker Sells 550,000 Shares

Stryker Corporation (NYSE:SYK) Director Ronda Stryker sold 550,000 shares of the company’s stock in a transaction that occurred on Friday, November 6th. The shares were sold at an average price of $325.32, for a total value of $178,926,000.00. Following the completion of the sale, the director owned 1,701,375 shares in the company, valued at approximately $553,491,315. This represents a 24.43% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink.

Stryker Price Performance

Shares of NYSE SYK traded down $0.17 during midday trading on Monday, reaching $325.69. 2,551,435 shares of the company traded hands, compared to its average volume of 2,514,437. Stryker Corporation has a 12 month low of $267.00 and a 12 month high of $389.33. The company has a debt-to-equity ratio of 0.60, a quick ratio of 1.30 and a current ratio of 2.18. The stock’s 50-day simple moving average is $292.37 and its 200-day simple moving average is $323.59. The firm has a market cap of $123.99 billion, a PE ratio of 34.69, a PEG ratio of 2.24 and a beta of 0.78.

Stryker (NYSE:SYK) last posted its earnings results on Thursday, October 29th. The medical technology company reported $3.52 earnings per share for the quarter, missing the consensus estimate of $3.55 by ($0.03). The firm had revenue of $6.52 billion during the quarter, compared to the consensus estimate of $6.62 billion. Stryker had a return on equity of 23.74% and a net margin of 13.78%. The firm’s revenue for the quarter was up 7.6% compared to the same quarter last year. During the same period in the previous year, the company posted $3.19 EPS. As a group, equities analysts anticipate that Stryker Corporation will post 14.84 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several analysts have recently commented on the stock. Raymond James Financial reissued an “outperform” rating and set a $323.00 price target (down from $370.00) on shares of Stryker in a research note on Friday, October 30th. Needham & Company LLC dropped their price objective on shares of Stryker from $418.00 to $359.00 and set a “buy” rating for the company in a research report on Friday, October 30th. Leerink Partners reduced their price objective on Stryker from $403.00 to $353.00 and set an “outperform” rating on the stock in a report on Friday, October 9th. Wall Street Zen lowered Stryker from a “buy” rating to a “hold” rating in a research report on Saturday, October 3rd. Finally, Johnson Rice lowered Stryker to a “hold” rating in a research report on Friday, October 30th. Twenty-one research analysts have rated the stock with a Buy rating and seven have assigned a Hold rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $342.19.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of the business. Nicholson Wealth Management Group LLC boosted its position in Stryker by 0.6% during the third quarter. Nicholson Wealth Management Group LLC now owns 5,184 shares of the medical technology company’s stock worth $1,428,000 after purchasing an additional 32 shares during the period. Pensioenfonds Rail & OV bought a new stake in shares of Stryker in the third quarter valued at approximately $5,739,000. IFG Advisory LLC raised its position in shares of Stryker by 1.7% in the third quarter. IFG Advisory LLC now owns 3,040 shares of the medical technology company’s stock valued at $837,000 after purchasing an additional 52 shares during the period. Optas LLC lifted its stake in shares of Stryker by 21.7% during the 3rd quarter. Optas LLC now owns 898 shares of the medical technology company’s stock valued at $247,000 after buying an additional 160 shares in the last quarter. Finally, Act Two Investors LLC lifted its stake in shares of Stryker by 13.8% during the 3rd quarter. Act Two Investors LLC now owns 57,147 shares of the medical technology company’s stock valued at $15,738,000 after buying an additional 6,930 shares in the last quarter. Institutional investors own 77.09% of the company’s stock.

Stryker Company Profile

Stryker is a medical technology company that develops and sells products and services for healthcare providers. Its offerings include orthopedic implants and surgical equipment, neurotechnology and spine products, and medical and surgical equipment used in hospitals and other care settings.

The company’s products also include patient-handling and emergency medical equipment, as well as instruments and technologies that support surgical procedures. Stryker serves healthcare customers in the United States and internationally.

Founded in 1941 by orthopedic surgeon Dr.